M. Charton, J. Motoc (Eds.) (1983). Steric Effects in Drug Design. Berlin: Springer.
K. C. Chu (1980). The quantitative analysis of structure–activity relationships. In: M. Wolff, ed.
The Basis of Medicinal Chemistry, 4th ed. Pa r t 1. New York: Wiley-Interscience.
Pp.393–418.
G. M. Crippen, T. F. Havel (1988). Distance Geometry and Molecular Conformation. New York:
Wiley.
J. M. Daniels, E. R. Nestmann, A. Kerr (1997). Development of stereoisomeric drugs: a brief
review of scientific and regulatory considerations. Drug Inf. J. 31: 639.
P. M. Dean (1990). Concepts and Applications of Molecular Similarity. New York: Wiley.
P. M. Dean (1995). Molecular Similarity in Drug Design. New York: Chapman and Hall.
J. N. Delgado, W. A. Remers (Eds.) (1998). Textbook of Organic Medicinal and Pharmaceutical
Chemistry.New York: Lippincott Williams and Wilkins.
F. Franks (Ed.). (1972).Water. A Comprehensive Treatise, vol. 1.The Physics and Physical
Chemistry of Water. New York: Plenum.
N. P. Franks, W. R. Lieb (1984).Do general anesthetics act by competitive binding to specific
receptors?Nature 310: 599–601.
A. K. Ghose, G. M. Crippen (1986). Atomic Physicochemical Paramotors for 3-D Quantitative
Structure–Activity Relationships. J. Comput. Chem. 7 : 565–577.
M. Gumbleton, W. Sneader (1994). Pharmacokinetic considerations in rational drug design.
Clinical Pharmacokinetics 26: 161.
L. P. Hammet (1970). Physical Organic Chemistry,2nd ed. New York: McGraw-Hill.
C. Hansch, A. Leo (1995). Exploring QSAR: vol.1, Fundamentals and Applications in Biology
and Chemistry. Washington: American Chemical Society.
E. Hines (2000). What’s new in excipients? Pharm. Formul. and Qual. 4: 24.
H. Kubinyi (1993). Hansch analysis and related approaches. In: R. Mannhold (Ed.). Methods and
Principles of Medicinal Chemistry, vol. 1.Weinheim: VCH.
I. D. Kuntz, E. Meng, B. Shoichet (1994). Structure based molecular design. Acc. Chem.
Res. 27: 117.
P. A. Lehman (1986). Stereoisomerism and drug action. Trends Pharmacol. Sci. 7: 281–285.
A. Leo, C. Hansch, D. Hoekman (1995). Exploring QSAR: Vol.2, Hydrophobic, Electronic and
Steric Constants. Washington: American Chemical Society.
C. A. Lipinski (1986). Bioisosterism in drug design. Ann. Rep. Med. Chem. 21 : 283.
B. Longoni, R. W. Olsen (1992). Studies of the mechanism of interaction of anesthetics with
GABA-A receptors. In: G. Biggio, E. Costa (Eds.).GABAergic Synaptic Transmission.
New York: Raven.
L. R. Low, N. Castagnoli (1978). Enantioselectivity in drug metabolism. Ann. Rep. Med. Chem.
13 : 304–315.
R. F. Rekker (1977).The Hydrophobic Fragmental Constant. New York: Elsevier.
R. F. Rekker, R. Mannhold (1992). Calculation of Drug Lipophilicity. Weinheim: VCH.
R. B. Silverman (1992). The Organic Chemistry of Drug Design and Drug Action.New York:
Academic Press.
S. C. Stinson (2001). Chiral pharmaceuticals. Chem. Eng. News. Oct. 1 : 79.
C. R. Symous (1981). Water structure and reactivity. Acc. Chem. Res. 14: 179–187.
A. Szent-Györgyi (1960). Introduction to Submolecular Biology. New York: Academic Press.
J. Uppenbrink, J. Mervis (2000). Drug discovery. Science 287: 1951.
A. Verloop (1987). The STERIMOL Approach to Drug Design. New York: Marcel Dekker.
C. G. Wermuth, C. R. Ganellin, P. Lindberg, L. A. Mitscher (1998). Terms used in medicinal
chemistry: IUPAC recommendations: 1997. Ann. Rep. Med. Chem. 33: 385.
M. E. Wolf (Ed.) (1995). Burger’s Medicinal Chemistry and Drug Discovery. New York: Wiley
Interscience.
64 MEDICINAL CHEMISTRY